LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Innoviva Inc

Suletud

SektorTervishoid

19.92 -1.73

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.64

Max

20.39

Põhinäitajad

By Trading Economics

Sissetulek

-67M

-47M

Müük

-3.2M

89M

P/E

Sektori keskmine

51.694

50.291

Aktsiakasum

-0.743

Kasumimarginaal

-52.559

Töötajad

127

EBITDA

-63M

-27M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+169.74% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

142M

1.3B

Eelmine avamishind

21.65

Eelmine sulgemishind

19.92

Uudiste sentiment

By Acuity

12%

88%

14 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Innoviva Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. juuni 2025, 23:49 UTC

Tulu

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. juuni 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. juuni 2025, 21:30 UTC

Tulu

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Tulu

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. juuni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. juuni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. juuni 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. juuni 2025, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. juuni 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. juuni 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. juuni 2025, 23:30 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. juuni 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. juuni 2025, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. juuni 2025, 22:06 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:15 UTC

Tulu

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. juuni 2025, 21:07 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. juuni 2025, 21:07 UTC

Tulu

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. juuni 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. juuni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 21:05 UTC

Omandamised, ülevõtmised, äriostud

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. juuni 2025, 20:52 UTC

Tulu

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. juuni 2025, 20:51 UTC

Tulu

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. juuni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Innoviva Inc Prognoos

Hinnasiht

By TipRanks

169.74% tõus

12 kuu keskmine prognoos

Keskmine 55 USD  169.74%

Kõrge 55 USD

Madal 55 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Innoviva Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

18.57 / 18.75Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

14 / 380 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.